Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three inhaled corticosteroids—beclometasone, budesonide, and fluticasone propionate. Each component is a synthetic glucocorticoid used primarily for the management and control of asthma and other inflammatory airway diseases. These drugs act by binding to the glucocorticoid receptor, leading to anti-inflammatory effects in the airways, reducing symptoms such as wheezing and shortness of breath. While each drug individually is widely used in clinical practice for asthma control, there are no known marketed products or clinical guidelines supporting their use together as a triple combination in a single formulation. The mechanism of action for all three involves suppression of airway inflammation through inhibition of multiple types of inflammatory cells (e.g., eosinophils) and mediators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclometasone + budesonide + fluticasone propionate.